cyclin-dependent kinase


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

cyclin-dependent kinase

Abbreviation: CDK
A family of enzymes involved in regulation of the cell cycle. They serve as targets for pharmacological manipulation of this cycle, particularly during the unregulated proliferation of tumor cells.
See also: kinase
References in periodicals archive ?
Butler, "Cyclin-dependent kinase 5 promotes pancreatic beta-cell survival via Fak-Akt signaling pathways," Diabetes, vol.
Cyclin-Dependent Kinases. Cyclin-dependent kinases (CDK) are serine/threonine protein kinases that bind to cyclin to mediate the phosphorylation reactions that are associated with the progression and regulation of the cell cycle [23].
Chan et al., "The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis," Cell Cycle, vol.
Abbreviations GC: Gastric cancer OD: Optical density CDK: Cyclin-dependent kinase PBS: Phosphate-buffered saline PI: Propidium iodide.
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816.
It prevents premature activation of cyclin E-cyclin-dependent kinase 2 in G1 and promotes the assembly and activation of D-type cyclin-dependent kinases. (20) Although the p27 gene is rarely mutated in human cancers, the action of p27 is impaired through a variety of mechanisms including proteolysis.
Subsequent work revealed that let-7 regulates a number of other oncogenes, including CCND2 (cyclin D2), CDK6 (cyclin-dependent kinase 6), CDC25 [cell division cycle 25 homolog C (S.
The growth inhibitory effect of ALA is not due to induction of apoptosis but instead is associated with an increase in the half-life of the cyclin-dependent kinase inhibitor, p27(kip1).
Results.--The ratio values considered significant (<0.5 or >1.5) suggest that genes up-regulated in parathyroid adenoma are those responsible for blood vessel angiogenesis and genes belonging to the cyclin-dependent kinase inhibitor groups.
Syros Pharmaceuticals announced preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor, showing synergistic anti-tumor activity in combination with carboplatin, a standard-of-care therapy, in models of ovarian cancer and providing a mechanistic rationale for the ongoing investigation of the combination in the Phase 1 clinical trial of SY-1365.
Alvocidib is a small molecule inhibitor of cyclin-dependent kinase 9 (CDK9) that controls the expression of a survival factor MCL-1, while Venetoclax is a small molecule inhibitor of B-cell lymphoma-2 (BCL-2).